Mário Henrique Magalhães Barros
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mário Henrique Magalhães Barros has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Rocio Hassan
Bone Marrow Transplantation Center, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil
11 shared publications - Gerald Niedobitek
Unfallkrankenhaus Berlin
7 shared publications Ilana R. Zalcberg
Bone Marrow Transplantation Center (CEMO), Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil
5 shared publications- Claudete Esteves Klumb
Programa de Pesquisa em Hemato-Oncologia Molecular, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
3 shared publications Elena De Matteo
3 shared publicationsRocio Hassan
Bone Marrow Transplantation Center, Instituto Nacional de Cancer (INCA), 20231-130 Rio de Janeiro, Brazil
3 shared publications
Latest Publications
- Open Access
- 1 December 2013
- Published by Elsevier in Cell Reports
- Vol. 5 (6) , 1489-1498
Human Natural Killer Cells Prevent Infectious Mononucleosis Features by Targeting Lytic Epstein-Barr Virus Infection
- 1 December 2013
- Published by Elsevier in Cell Reports
- Vol. 5 (6) , 1489-1498
Open AccessHuman Natural Killer Cells Prevent Infectious Mononucleosis Features by Targeting Lytic Epstein-Barr Virus Infection
- Open Access
- 15 November 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (11) , e80908
Macrophage Polarisation: an Immunohistochemical Approach for Identifying M1 and M2 Macrophages
Macrophage polarization is increasingly recognised as an important pathogenetic factor in inflammatory and neoplastic diseases. Proinflammatory M1 macrophages promote T helper (Th) 1 responses and show tumoricidal activity. M2 macrophages contribute to tissue repair and promote Th2 responses. CD68 and CD163 are used to identify macrophages in tissue sections. However, characterisation of polarised macrophages in situ has remained difficult. Macrophage polarisation is regulated by transcription factors, pSTAT1 and RBP-J for M1, and CMAF for M2. We reasoned that double-labelling immunohistochemistry for the detection of macrophage markers together with transcription factors may be suitable to characterise macrophage polarisation in situ. To test this hypothesis, we have studied conditions associated with Th1- and Th2-predominant immune responses: infectious mononucleosis and Crohn’s disease for Th1 and allergic nasal polyps, oxyuriasis, wound healing and foreign body granulomas for predominant Th2 response. In all situations, CD163+ cells usually outnumbered CD68+ cells. Moreover, CD163+ cells, usually considered as M2 macrophages, co-expressing pSTAT1 and RBP-J were found in all conditions examined. The numbers of putative M1 macrophages were higher in Th1- than in Th2-associated diseases, while more M2 macrophages were seen in Th2- than in Th1 related disorders. In most Th1-related diseases, the balance of M1 over M2 cells was shifted towards M1 cells, while the reverse was observed for Th2-related conditions. Hierarchical cluster analysis revealed two distinct clusters: cluster I included Th1 diseases together with cases with high numbers of CD163+pSTAT1+, CD68+pSTAT1+, CD163+RBP-J+ and CD68+RBP-J+ macrophages; cluster II comprised Th2 conditions together with cases displaying high numbers of CD163+CMAF+ and CD68+CMAF+ macrophages. These results suggest that the detection of pSTAT1, RBP-J, and CMAF in the context of CD68 or CD163 expression is a suitable tool for the characterisation of macrophage polarisation in situ. Furthermore, CD163 cannot be considered a reliable M2 marker when used on its own.
- 15 November 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (11) , e80908
Open AccessMacrophage Polarisation: an Immunohistochemical Approach for Identifying M1 and M2 Macrophages
Macrophage polarization is increasingly recognised as an important pathogenetic factor in inflammatory and neoplastic diseases. Proinflammatory M1 macrophages promote T helper (Th) 1 responses and show tumoricidal activity. M2 macrophages contribute to tissue repair and promote Th2 responses. CD68 and CD163 are used to identify macrophages in tissue sections. However, characterisation of polarised macrophages in situ has remained difficult. Macrophage polarisation is regulated by transcription factors, pSTAT1 and RBP-J for M1, and CMAF for M2. We reasoned that double-labelling immunohistochemistry for the detection of macrophage markers together with transcription factors may be suitable to characterise macrophage polarisation in situ. To test this hypothesis, we have studied conditions associated with Th1- and Th2-predominant immune responses: infectious mononucleosis and Crohn’s disease for Th1 and allergic nasal polyps, oxyuriasis, wound healing and foreign body granulomas for predominant Th2 response. In all situations, CD163+ cells usually outnumbered CD68+ cells. Moreover, CD163+ cells, usually considered as M2 macrophages, co-expressing pSTAT1 and RBP-J were found in all conditions examined. The numbers of putative M1 macrophages were higher in Th1- than in Th2-associated diseases, while more M2 macrophages were seen in Th2- than in Th1 related disorders. In most Th1-related diseases, the balance of M1 over M2 cells was shifted towards M1 cells, while the reverse was observed for Th2-related conditions. Hierarchical cluster analysis revealed two distinct clusters: cluster I included Th1 diseases together with cases with high numbers of CD163+pSTAT1+, CD68+pSTAT1+, CD163+RBP-J+ and CD68+RBP-J+ macrophages; cluster II comprised Th2 conditions together with cases displaying high numbers of CD163+CMAF+ and CD68+CMAF+ macrophages. These results suggest that the detection of pSTAT1, RBP-J, and CMAF in the context of CD68 or CD163 expression is a suitable tool for the characterisation of macrophage polarisation in situ. Furthermore, CD163 cannot be considered a reliable M2 marker when used on its own.
- 17 March 2013
- Published by Springer Nature in Virchows Archiv
- Vol. 462 (4) , 381-389
Detection of HPV infection in head and neck squamous cell carcinoma: a practical proposal
Detecting human papillomavirus (HPV) infection in head and neck squamous cell carcinoma (HNSCC) is clinically relevant, but there is no agreement about the most appropriate methodology. We have studied 64 oropharyngeal carcinomas using p16 immunohistochemistry, HPV DNA in situ hybridisation (ISH) and HPV DNA polymerase chain reaction (PCR) followed by pyrosequencing. We have also evaluated a new assay, RNAscope, designed to detect HPV E6/E7 RNA transcripts. Using a threshold of 70 % labelled tumour cells, 21 cases (32.8 %) were p16 positive. Of these, 19 cases scored positive with at least one HPV detection assay. Sixteen cases were positive by HPV DNA-ISH, and 18 cases were positive using the E6/E7 RNAscope assay. By PCR and pyrosequencing, HPV16 was detected in 15 cases, while one case each harboured HPV33, 35 and 56. All p16-negative cases were negative using these assays. We conclude that p16 expression is a useful surrogate marker for HPV infection in HNSCC with a high negative predictive value and that p16-positive cases should be further evaluated for HPV infection, preferably by PCR followed by type determination. Using RNase digestion experiments, we show that the RNAscope assay is not suitable for the reliable discrimination between E6/E7 RNA transcripts and viral DNA.
- 17 March 2013
- Published by Springer Nature in Virchows Archiv
- Vol. 462 (4) , 381-389
Detection of HPV infection in head and neck squamous cell carcinoma: a practical proposal
Detecting human papillomavirus (HPV) infection in head and neck squamous cell carcinoma (HNSCC) is clinically relevant, but there is no agreement about the most appropriate methodology. We have studied 64 oropharyngeal carcinomas using p16 immunohistochemistry, HPV DNA in situ hybridisation (ISH) and HPV DNA polymerase chain reaction (PCR) followed by pyrosequencing. We have also evaluated a new assay, RNAscope, designed to detect HPV E6/E7 RNA transcripts. Using a threshold of 70 % labelled tumour cells, 21 cases (32.8 %) were p16 positive. Of these, 19 cases scored positive with at least one HPV detection assay. Sixteen cases were positive by HPV DNA-ISH, and 18 cases were positive using the E6/E7 RNAscope assay. By PCR and pyrosequencing, HPV16 was detected in 15 cases, while one case each harboured HPV33, 35 and 56. All p16-negative cases were negative using these assays. We conclude that p16 expression is a useful surrogate marker for HPV infection in HNSCC with a high negative predictive value and that p16-positive cases should be further evaluated for HPV infection, preferably by PCR followed by type determination. Using RNase digestion experiments, we show that the RNAscope assay is not suitable for the reliable discrimination between E6/E7 RNA transcripts and viral DNA.
- Open Access
- 27 September 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (9) , e46005
Relationship of Epstein-Barr Virus and Interleukin 10 Promoter Polymorphisms with the Risk and Clinical Outcome of Childhood Burkitt Lymphoma
Epstein-Barr virus (EBV) is an important environmental factor associated to the development of Burkitt lymphoma (BL) in endemic and intermediate risk regions. However, little is known about the contribution of genetic constitution to the development and clinical response of the disease. The aim of this work was to investigate the role of EBV and Interleukin 10 (IL10) single nucleotide polymorphisms (−1082A/G, −819C/T, −592C/A) and microsatellites (IL10.R and IL10.G) in susceptibility and clinical outcome in pediatric BL patients, in a region with intermediate EBV association frequency. The frequencies of IL10 promoter Single nucleotide polymorphisms −1082A/G, −819C/T, −592C/A, and IL10.R and IL10.G microsatellites were compared in 62 pediatric patients and 216 healthy donors. IL10 −1082GG and GCC/GCC genotypes were more frequent in patients than in controls, and associated to a higher risk of BL development (GG genotype OR 2.62, 95% CI, 1.25–5.51; P = 0.008; Pc = 0.024). EBV was detected in tumor samples by EBER-ISH in 54.1% of cases. EBV+ patients exhibited a better event free survival (EFS) (P = 0.019) than EBV− patients. Carriers of IL10 R3-GCC had worse EFS (P = 0.028). Our results suggest a risk effect and an independent prognostic value of IL10 polymorphisms and EBV in childhood BL patients.
- 27 September 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (9) , e46005
Open AccessRelationship of Epstein-Barr Virus and Interleukin 10 Promoter Polymorphisms with the Risk and Clinical Outcome of Childhood Burkitt Lymphoma
Epstein-Barr virus (EBV) is an important environmental factor associated to the development of Burkitt lymphoma (BL) in endemic and intermediate risk regions. However, little is known about the contribution of genetic constitution to the development and clinical response of the disease. The aim of this work was to investigate the role of EBV and Interleukin 10 (IL10) single nucleotide polymorphisms (−1082A/G, −819C/T, −592C/A) and microsatellites (IL10.R and IL10.G) in susceptibility and clinical outcome in pediatric BL patients, in a region with intermediate EBV association frequency. The frequencies of IL10 promoter Single nucleotide polymorphisms −1082A/G, −819C/T, −592C/A, and IL10.R and IL10.G microsatellites were compared in 62 pediatric patients and 216 healthy donors. IL10 −1082GG and GCC/GCC genotypes were more frequent in patients than in controls, and associated to a higher risk of BL development (GG genotype OR 2.62, 95% CI, 1.25–5.51; P = 0.008; Pc = 0.024). EBV was detected in tumor samples by EBER-ISH in 54.1% of cases. EBV+ patients exhibited a better event free survival (EFS) (P = 0.019) than EBV− patients. Carriers of IL10 R3-GCC had worse EFS (P = 0.028). Our results suggest a risk effect and an independent prognostic value of IL10 polymorphisms and EBV in childhood BL patients.
- 15 July 2012
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (14) , 3762-3771
Tumor-Associated Macrophages in Pediatric Classical Hodgkin Lymphoma: Association with Epstein-Barr Virus, Lymphocyte Subsets, and Prognostic Impact
Purpose: Tumor-infiltrating macrophages are associated with adverse outcome in adult classical Hodgkin lymphoma (cHL). We have previously shown age-related changes in the lymphocyte composition of pediatric cHL. We therefore hypothesized that the number, function, and prognostic impact of macrophages in pediatric cHL would be different from adult cases.
- 15 July 2012
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (14) , 3762-3771
Tumor-Associated Macrophages in Pediatric Classical Hodgkin Lymphoma: Association with Epstein-Barr Virus, Lymphocyte Subsets, and Prognostic Impact
Purpose: Tumor-infiltrating macrophages are associated with adverse outcome in adult classical Hodgkin lymphoma (cHL). We have previously shown age-related changes in the lymphocyte composition of pediatric cHL. We therefore hypothesized that the number, function, and prognostic impact of macrophages in pediatric cHL would be different from adult cases.
- 1 May 2012
- Published by Microbiology Society in Journal of General Virology
- Vol. 93 (5) , 1059-1064
Lytic Epstein–Barr virus infection in epithelial cells but not in B-lymphocytes is dependent on Blimp1
Epstein–Barr virus (EBV) replicates in superficial differentiated cells of oral hairy leukoplakia (OHL). Differentiation of squamous epithelial cells depends on B-lymphocyte-induced maturation protein 1 (Blimp1). Here we show that expression of the EBV immediate-early protein BZLF1 is restricted to Blimp1-positive epithelial cells in OHL. Luciferase assays revealed Blimp1-dependent induction of the BZLF1 promoter Zp in epithelial cell lines. Expression of ZEB1, a negative regulator of Zp, and of Xbp-1, which mediates the Blimp1 effect on Zp in B-cells, was not affected by enforced Blimp1 expression. Moreover, Xbp-1 protein expression was not detected in differentiated epithelial cells of OHL. Thus, Blimp1 induces BZLF1 expression in epithelial cells independently of ZEB1 and Xbp-1. In contrast to epithelial cells of OHL, BZLF1 expression was also observed in Blimp1-negative lymphoid cells in infectious mononucleosis tonsils, suggesting that EBV replication in B-cells may be induced independently of terminal differentiation.
- 1 May 2012
- Published by Microbiology Society in Journal of General Virology
- Vol. 93 (5) , 1059-1064
Lytic Epstein–Barr virus infection in epithelial cells but not in B-lymphocytes is dependent on Blimp1
Epstein–Barr virus (EBV) replicates in superficial differentiated cells of oral hairy leukoplakia (OHL). Differentiation of squamous epithelial cells depends on B-lymphocyte-induced maturation protein 1 (Blimp1). Here we show that expression of the EBV immediate-early protein BZLF1 is restricted to Blimp1-positive epithelial cells in OHL. Luciferase assays revealed Blimp1-dependent induction of the BZLF1 promoter Zp in epithelial cell lines. Expression of ZEB1, a negative regulator of Zp, and of Xbp-1, which mediates the Blimp1 effect on Zp in B-cells, was not affected by enforced Blimp1 expression. Moreover, Xbp-1 protein expression was not detected in differentiated epithelial cells of OHL. Thus, Blimp1 induces BZLF1 expression in epithelial cells independently of ZEB1 and Xbp-1. In contrast to epithelial cells of OHL, BZLF1 expression was also observed in Blimp1-negative lymphoid cells in infectious mononucleosis tonsils, suggesting that EBV replication in B-cells may be induced independently of terminal differentiation.
- 25 October 2011
- Published by Wiley in International Journal of Cancer
- Vol. 131 (5) , 1142-1152
Tumor microenvironment composition in pediatric classical Hodgkin lymphoma is modulated by age and Epstein‐Barr virus infection
Classical Hodgkin lymphoma (cHL) is characterized by a small number of neoplastic cells in a background of reactive cells. Children and adults differ in constitution and functionality of the immune system and it is possible that there may be age‐related differences in tumor microenvironment composition in cHL. One hundred children with pediatric cHL were studied. Tumor‐infiltrating lymphocytes were analyzed by immunohistochemistry (IHC) and image analysis. Epstein‐Barr virus (EBV) status was determined by EBER‐specific in situ hybridization and IHC. Results were analyzed in the context of age‐group, histological characteristics and clinical follow‐up. EBV‐status was not associated with age‐group. Children p = 0.016) and high number of GranzymeB+ lymphocytes (p = 0.04) were independently associated with reduced progression‐free survival (PFS). Yet, in EBV+ cases, improved outcome was observed in cases with low numbers of FOXP3+ lymphocytes (p = 0.046), FOXP3/CD8 ratio < 1 (p = 0.021) and TBET/CMAF ratio < 1 (p = 0.017). By contrast, in EBV− cases, poor survival was observed in cases with extranodal disease (p = 0.028), MC subtype (p = 0.009) and high numbers of TIA1+ (p = 0.044) and GranzymeB+ (p = 0.04) lymphocytes. The results suggest that in EBV+ cHL an effective immune response directed against viral or tumor antigens may be triggered in the tumor microenvironment and that physiological and age‐related changes of the immune system may also modulate the tumor microenvironment in pediatric cHL.
- 25 October 2011
- Published by Wiley in International Journal of Cancer
- Vol. 131 (5) , 1142-1152
Tumor microenvironment composition in pediatric classical Hodgkin lymphoma is modulated by age and Epstein‐Barr virus infection
Classical Hodgkin lymphoma (cHL) is characterized by a small number of neoplastic cells in a background of reactive cells. Children and adults differ in constitution and functionality of the immune system and it is possible that there may be age‐related differences in tumor microenvironment composition in cHL. One hundred children with pediatric cHL were studied. Tumor‐infiltrating lymphocytes were analyzed by immunohistochemistry (IHC) and image analysis. Epstein‐Barr virus (EBV) status was determined by EBER‐specific in situ hybridization and IHC. Results were analyzed in the context of age‐group, histological characteristics and clinical follow‐up. EBV‐status was not associated with age‐group. Children p = 0.016) and high number of GranzymeB+ lymphocytes (p = 0.04) were independently associated with reduced progression‐free survival (PFS). Yet, in EBV+ cases, improved outcome was observed in cases with low numbers of FOXP3+ lymphocytes (p = 0.046), FOXP3/CD8 ratio < 1 (p = 0.021) and TBET/CMAF ratio < 1 (p = 0.017). By contrast, in EBV− cases, poor survival was observed in cases with extranodal disease (p = 0.028), MC subtype (p = 0.009) and high numbers of TIA1+ (p = 0.044) and GranzymeB+ (p = 0.04) lymphocytes. The results suggest that in EBV+ cHL an effective immune response directed against viral or tumor antigens may be triggered in the tumor microenvironment and that physiological and age‐related changes of the immune system may also modulate the tumor microenvironment in pediatric cHL.
- 4 March 2011
- Published by Wiley in Hematological Oncology
- Vol. 29 (4) , 190-195
Disease patterns in pediatric classical Hodgkin lymphoma: a report from a developing area in Brazil
Epidemiological patterns established about 20 years ago, divided classical Hodgkin lymphoma (cHL) in three entities with regard to Epstein–Barr virus (EBV) status and histological subtypes and suggested different epidemiological patterns associated with degree of economic development. Here, we investigated histopathological features and EBV association in 100 consecutive pediatric cHL cases occurring in Rio de Janeiro (Brazil). Age at diagnosis ranged from 3 to 18 years (median 14 years) with 27% of cases ≤10 years. Unexpectedly, we did not observe an early childhood peak with most cases occurring in the >10 years age group. Nodular sclerosis (NS) was the most frequent subtype (69%) and was more frequently observed in the >10 years age group, followed by mixed cellularity (MC, 23%) which was distributed equally between age groups. EBV was identified in 44.8% of cases, without preferential association with age groups (≤10 years vs. >10 years). MC cases were independently associated with EBV infection of tumour cells (p = 0.045) and with a CD4/CD20 ratio p = 0.014). Our results suggest that a gradual shift from childhood peak to early adulthood peak may be observed in developing regions. The development of MC subtype may result from early exposure to EBV in the context of an impaired immune system reflected by a CD4/CD20 ratio <1. Conversely, it is possible that NS originates predominantly in the context of a better immune response against EBV and/or tumour antigens expressed in the neoplastic cells. Copyright © 2011 John Wiley & Sons, Ltd.
- 4 March 2011
- Published by Wiley in Hematological Oncology
- Vol. 29 (4) , 190-195
Disease patterns in pediatric classical Hodgkin lymphoma: a report from a developing area in Brazil
Epidemiological patterns established about 20 years ago, divided classical Hodgkin lymphoma (cHL) in three entities with regard to Epstein–Barr virus (EBV) status and histological subtypes and suggested different epidemiological patterns associated with degree of economic development. Here, we investigated histopathological features and EBV association in 100 consecutive pediatric cHL cases occurring in Rio de Janeiro (Brazil). Age at diagnosis ranged from 3 to 18 years (median 14 years) with 27% of cases ≤10 years. Unexpectedly, we did not observe an early childhood peak with most cases occurring in the >10 years age group. Nodular sclerosis (NS) was the most frequent subtype (69%) and was more frequently observed in the >10 years age group, followed by mixed cellularity (MC, 23%) which was distributed equally between age groups. EBV was identified in 44.8% of cases, without preferential association with age groups (≤10 years vs. >10 years). MC cases were independently associated with EBV infection of tumour cells (p = 0.045) and with a CD4/CD20 ratio p = 0.014). Our results suggest that a gradual shift from childhood peak to early adulthood peak may be observed in developing regions. The development of MC subtype may result from early exposure to EBV in the context of an impaired immune system reflected by a CD4/CD20 ratio <1. Conversely, it is possible that NS originates predominantly in the context of a better immune response against EBV and/or tumour antigens expressed in the neoplastic cells. Copyright © 2011 John Wiley & Sons, Ltd.
- 27 July 2010
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 51 (8) , 1513-1526
Cell cycle characteristics and Epstein–Barr virus are differentially associated with aggressive and non-aggressive subsets of Hodgkin lymphoma in pediatric patients
We investigated the correlation of tumor characteristics with clinico-biological markers of aggressive disease, evaluated by Ann Arbor stage, risk group, B-symptoms, number of involved anatomic areas, mediastinal mass, nodular sclerosis (NS) grade, and risk, in pediatric Hodgkin lymphoma (HL). Leukopenia and extranodal disease influenced event-free survival (p = 0.032 and p = 0.041). In multivariate analysis, extranodal disease was associated with high number of tumor-infiltrating eosinophils (p = 0.035) and Ki67 < 50% (p = 0.024); B-symptoms with Ki67 > or =75% (p = 0.027) and high LDH levels (p = 0.001); and mediastinal mass with leukopenia (p = 0.048), NS grade II (p = 0.025), and high-risk (p = 0.046). Furthermore, low stages correlated with Ki67 > or =50% (p = 0.005) and Epstein-Barr virus (EBV) (p = 0.065). Low-risk NS was associated with EBV (p = 0.014). Hierarchical cluster analysis identified two clusters, one composed of high-risk patients and cell cycle and apoptosis features, and the other including low-risk patients, EBV, and low-risk NS. Our results show the association of biological markers with disease aggressiveness in pediatric HL.
- 27 July 2010
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 51 (8) , 1513-1526
Cell cycle characteristics and Epstein–Barr virus are differentially associated with aggressive and non-aggressive subsets of Hodgkin lymphoma in pediatric patients
We investigated the correlation of tumor characteristics with clinico-biological markers of aggressive disease, evaluated by Ann Arbor stage, risk group, B-symptoms, number of involved anatomic areas, mediastinal mass, nodular sclerosis (NS) grade, and risk, in pediatric Hodgkin lymphoma (HL). Leukopenia and extranodal disease influenced event-free survival (p = 0.032 and p = 0.041). In multivariate analysis, extranodal disease was associated with high number of tumor-infiltrating eosinophils (p = 0.035) and Ki67 < 50% (p = 0.024); B-symptoms with Ki67 > or =75% (p = 0.027) and high LDH levels (p = 0.001); and mediastinal mass with leukopenia (p = 0.048), NS grade II (p = 0.025), and high-risk (p = 0.046). Furthermore, low stages correlated with Ki67 > or =50% (p = 0.005) and Epstein-Barr virus (EBV) (p = 0.065). Low-risk NS was associated with EBV (p = 0.014). Hierarchical cluster analysis identified two clusters, one composed of high-risk patients and cell cycle and apoptosis features, and the other including low-risk patients, EBV, and low-risk NS. Our results show the association of biological markers with disease aggressiveness in pediatric HL.
- 22 March 2010
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 54 (7) , 904-908
MTRpolymorphic variant A2756G and retinoblastoma risk in Brazilian children
Background: Polymorphisms in the genes of folate and methionine metabolism enzymes have been associated with some forms of cancer by affecting DNA synthesis, repair, and methylation.Procedure: A case–control study of 72 retinoblastoma cases and 98 cancer‐free children controls was performed to investigate whether the polymorphisms of the methylenetetrahydrofolate reductase (MTHFRC677T and A1298C), methionine synthase (MTRA2756G), carrier of reduced folate 1 (RFC‐1 A80G) and thymidylate synthase (TYMS2R > 3R) altered the risk for retinoblastoma.Results: MTRA2756G AG plus GG genotype frequencies were higher in patients than in controls (45% vs. 26%,P = 0.03). Individual carriers of the variant allele G had a 2.02 (95% CI: 1.05–3.92)‐fold increased risk for retinoblastoma. In contrast, no association was observed with respect toMTHFRC677T and A1298C,RFCA80G, andTYMSpolymorphisms.Conclusions: This study presents evidence for an association between theMTRA2756G polymorphism and retinoblastoma susceptibility in a Northeast population from Brazil. Pediatr Blood Cancer 2010;54:904–908
- 22 March 2010
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 54 (7) , 904-908
MTRpolymorphic variant A2756G and retinoblastoma risk in Brazilian children
Background: Polymorphisms in the genes of folate and methionine metabolism enzymes have been associated with some forms of cancer by affecting DNA synthesis, repair, and methylation.Procedure: A case–control study of 72 retinoblastoma cases and 98 cancer‐free children controls was performed to investigate whether the polymorphisms of the methylenetetrahydrofolate reductase (MTHFRC677T and A1298C), methionine synthase (MTRA2756G), carrier of reduced folate 1 (RFC‐1 A80G) and thymidylate synthase (TYMS2R > 3R) altered the risk for retinoblastoma.Results: MTRA2756G AG plus GG genotype frequencies were higher in patients than in controls (45% vs. 26%,P = 0.03). Individual carriers of the variant allele G had a 2.02 (95% CI: 1.05–3.92)‐fold increased risk for retinoblastoma. In contrast, no association was observed with respect toMTHFRC677T and A1298C,RFCA80G, andTYMSpolymorphisms.Conclusions: This study presents evidence for an association between theMTRA2756G polymorphism and retinoblastoma susceptibility in a Northeast population from Brazil. Pediatr Blood Cancer 2010;54:904–908